UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 52,297 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 10.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 460,012 shares of the company's stock after selling 52,297 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.45% of Intellia Therapeutics worth $9,453,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP grew its position in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock valued at $29,648,000 after purchasing an additional 98,865 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in Intellia Therapeutics in the second quarter worth $679,000. American Century Companies Inc. grew its position in Intellia Therapeutics by 23.8% in the second quarter. American Century Companies Inc. now owns 330,514 shares of the company's stock worth $7,397,000 after acquiring an additional 63,550 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Intellia Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock worth $17,006,000 after acquiring an additional 37,714 shares in the last quarter. Finally, FMR LLC grew its position in Intellia Therapeutics by 5.0% in the third quarter. FMR LLC now owns 2,339,522 shares of the company's stock worth $48,077,000 after acquiring an additional 111,104 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 12th. Wells Fargo & Company lowered their price target on shares of Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating for the company in a research note on Monday, November 18th. Wedbush reissued a "neutral" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $54.94.

Insider Activity

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.20% of the company's stock.

Intellia Therapeutics Price Performance

NTLA stock traded down $0.10 during trading on Monday, reaching $14.62. The company had a trading volume of 1,898,352 shares, compared to its average volume of 1,756,186. Intellia Therapeutics, Inc. has a 52 week low of $12.82 and a 52 week high of $34.87. The company has a market cap of $1.49 billion, a P/E ratio of -2.69 and a beta of 1.76. The business has a 50 day moving average of $16.49 and a 200 day moving average of $20.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts' expectations of $8.28 million. During the same quarter last year, the company posted ($1.38) EPS. Intellia Therapeutics's revenue for the quarter was down 24.1% compared to the same quarter last year. Research analysts expect that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.